CIK 0001035354
- Non-accelerated filer
- Smaller reporting company
Eloxx Pharmaceuticals, Inc.
Sign in to watch- Ticker
- ELOX
- Exchange
- Nasdaq
- Industry
- Biological Products, (No Diagnostic Substances)
- FY end
- Dec 31
- Incorporated
- DE
- Entity type
- Operating
- EIN
- 841368850
- Phone
- +1 781-577-5300
- Business address
- P.O. BOX 274, ARLINGTON, MA, 02476
- Former names
- Sevion Therapeutics, Inc., SENESCO TECHNOLOGIES INC, NAVA LEISURE USA INC
- Open-market buys, last 90 days
- $0
- in 0 filings
- Open-market sales, last 90 days
- $0
- in 0 filings
Shares bought or sold at a price by officers, directors and 10% owners (Form 4 codes P and S). Grants, option exercises and tax withholding aren't counted.
Reading 100 more Form 4s from the SEC; this list fills in as they're read.
| Date | Insider | Transaction | Shares | Price | Value | Owned after |
|---|---|---|---|---|---|---|
| 2014-11-18 | FORBES CHRISTOPHER Director | Grant or award · Common Stock Option (right to buy) | +27,882 | 64,107 | ||
| 2014-11-18 | FORBES CHRISTOPHER Director | Grant or award · Common Stock Option (right to buy) | +3,462 | $0.42 | $1K | 67,569 |
| 2014-05-14 | FORBES CHRISTOPHER Director | Grant or award · Common Stock Option | +17,464 | 36,406 | ||
| 2013-09-13 | FORBES CHRISTOPHER Director | Grant or award · Common Stock Option | +318,000 | 2,002,193 | ||
| 2013-05-17 | FORBES CHRISTOPHER Director | Grant or award · Common Stock Option | +238,372 | 1,684,193 | ||
| 2013-02-19 | FORBES CHRISTOPHER Director | Grant or award · Common Stock Option | +89,016 | 1,495,821 | ||
| 2012-11-26 | FORBES CHRISTOPHER Director | Purchase | +2,500 | $0.16 | $400 | 12,757,318 |
| 2012-11-16 | FORBES CHRISTOPHER Director | Grant or award · Common Stock Options | +252,000 | 1,302,563 | ||
| 2012-11-16 | FORBES CHRISTOPHER Director | Grant or award · Common Stock Options | +124,242 | 1,426,805 | ||
| 2012-08-08 | FORBES CHRISTOPHER Director | Conversion | +4,292,583 | $0.26 | $1.1M | 12,754,818 |
| 2012-08-08 | FORBES CHRISTOPHER Director | Conversion · Series B Convertible Preferred Stock | −1,000 | 0 | ||
| 2012-05-16 | FORBES CHRISTOPHER Director | Grant or award · Common Stock Option | +35,366 | 1,050,563 | ||
| 2012-02-16 | FORBES CHRISTOPHER Director | Grant or award · Common Stock Option | +36,458 | 1,015,197 | ||
| 2012-01-06 | FORBES CHRISTOPHER Director | Purchase | +192,308 | $0.26 | $50K | 8,239,021 |
| 2011-11-16 | FORBES CHRISTOPHER Director | Grant or award · Common Stock Option | +87,500 | 1,018,739 | ||
| 2011-09-30 | FORBES CHRISTOPHER Director | Grant or award · Common Stock Option | +190,000 | 931,239 | ||
| 2011-05-17 | FORBES CHRISTOPHER Director | Grant or award · Common Stock Option | +37,962 | 741,239 | ||
| 2011-03-22 | FORBES CHRISTOPHER Director | Purchase | +15,000 | $0.28 | $4K | 7,452,289 |
| 2011-02-14 | FORBES CHRISTOPHER Director | Grant or award · Common Stock Option | +32,758 | 703,277 | ||
| 2010-11-17 | FORBES CHRISTOPHER Director | Grant or award · Common Stock Option | +125,000 | 603,211 |
Page 1 of 3 · 59 trades